ARTICLE SUMMARY:
In the ALLEVIATE-HF clinical trial, continuous monitoring provided by Medtronic’s insertable cardiac monitor revealed a substantial burden of previously unsuspected arrhythmias in patients with both HFrEF and HFpEF—many of whom would not ordinarily qualify for an implantable cardiac device.
ALLEVIATE-HF was a randomized clinical trial sponsored by Medtronic that studied the use of the company’s Reveal LINQ insertable cardiac monitor (ICM) in heart failure patients who did not already have a cardiac implantable electronic device (CIED)—a category that includes permanent pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices.
The trial’s primary objective was to determine whether, over 13 months, medical management aimed at alleviating congestion and guided by a risk score derived from data collected by the Reveal LINQ could improve outcomes.
